PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Phase 2 Completed 63 enrolled Mesoblast, Inc. Juvenile Diabetes Research Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.

Timeline

Start: 2008-06-11
Primary completion: 2010-12-12
Completion: 2011-12-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prochymal®	Cell therapy	—	Intravenous

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Summary

Timeline

Drugs

Indications